How should an inflammatory-type polyp be managed?

Management of Inflammatory-Type Polyps

For inflammatory polyps in the gastrointestinal tract, targeted biopsies of representative or concerning lesions are appropriate, but removal and sampling of all lesions is neither required nor practical. 1

Key Management Principles

In IBD-Associated Inflammatory Polyps (Pseudopolyps)

The most recent and authoritative guidance comes from the 2021 AGA Clinical Practice Update, which provides clear direction:

• Targeted biopsy approach: Take biopsies only of representative or concerning pseudopolyps during colonoscopy 1
• Not all lesions require removal: Complete removal of all inflammatory polyps is neither necessary nor feasible 1
• Surgery is a last resort: Reserve surgical intervention only for managing colorectal cancer risk in severe pseudopolyposis that cannot be managed endoscopically 1

Important caveat: Dye spray chromoendoscopy should NOT be used to detect flat or subtle lesions within a field of pseudopolyps, as this technique is not helpful in this specific context 1.

Surveillance Considerations

Post-inflammatory polyps (pseudopolyps) serve as markers of previous severe inflammation and are associated with:

• Greater severity and extent of colonic inflammation
• Increased colectomy risk
• However, recent evidence does NOT show a clear association with colorectal neoplasia 2

This means that while these polyps indicate more aggressive disease, they themselves don't necessarily increase cancer risk beyond what the underlying inflammation already confers.

Surveillance Intervals for IBD Patients with Pseudopolyps

According to British Society of Gastroenterology guidelines, patients with post-inflammatory polyps fall into the intermediate risk category, requiring surveillance colonoscopy every 3 years 2.

Non-IBD Inflammatory Polyps

Inflammatory Fibroid Polyps (IFPs)

These are rare benign lesions with distinct management:

Size-based decision algorithm:

• Lesions ≤1.65 cm: Endoscopic resection is appropriate (82.6% sensitivity, 74.7% specificity for this cutoff) 3
• Lesions >1.65 cm: Consider surgical resection, especially if symptomatic 3

Location-based algorithm:

• Gastric or colorectal IFPs: Endoscopic resection is first-line treatment 3, 4
• Small intestinal (jejunum/ileum) IFPs: Primary surgical resection is indicated (20.6-fold increased likelihood of requiring surgery vs. gastric location) 3

Key point: Size alone should not dictate surgery for colonic IFPs—location and morphology matter more. Large colonic IFPs can be successfully removed endoscopically without complication 4.

Inflammatory Cloacogenic Polyps

These anorectal lesions associated with mucosal prolapse syndrome require:

• Surgery is indicated if malignancy cannot be excluded or if the patient is symptomatic 5
• These can mimic malignant lesions endoscopically, making definitive diagnosis crucial

Practical Algorithm

1. Identify polyp type and location

   • IBD-associated pseudopolyps → targeted biopsy only
   • Inflammatory fibroid polyp → assess size and location
   • Cloacogenic polyp → assess for malignancy features

2. For IFPs, apply dual criteria:

   • Small bowel location → surgery
   • Gastric/colonic + >1.65 cm → consider surgery
   • Gastric/colonic + ≤1.65 cm → endoscopic resection

3. Avoid common pitfalls:

   • Don't attempt complete removal of all pseudopolyps in IBD
   • Don't use chromoendoscopy within pseudopolyp fields
   • Don't assume all large polyps require surgery—location matters

Follow-up

For IBD patients with pseudopolyps, continue surveillance at 3-year intervals, adjusting based on disease activity, patient preference, and examination quality 2.